Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?
Gastroenterology and hepatology from bed to bench. · 01.01.2025 · 18 (3) · 342-352
DOI: 10.22037/ghfbb.v18i3.3033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology and hepatology from bed to bench., erschienen am 01.01.2025. Verfasst von Ömer Keskin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
In this study, we investigated the relationship between serum uric acid (SUA) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients detected through abdominal ultrasound. The second aim was to determine if there were any gender differences.
Background
High SUA levels may contribute to the mechanisms underlying various metabolic disorders, including MASLD.
Methods
We conducted a retrospective study among patients older than 18 who had been admitted to a tertiary hospital's gastroenterology outpatient clinic for over two years. A total of 200 patients diagnosed with either Grade 1, 2, or 3 hepatosteatosis by ultrasound screening and 200 patients without hepatosteatosis were included in the study. Patients' demographic features, laboratory parameters, and detailed medical history were extracted from the hospital's medical records.
Results
The mean age of the 400 patients enrolled in the study was 47.92±0.78 years, and 70.25% were men. SUA (5.34 mg/dL ± 1.52 vs. 4.64 mg/dL ± 1.28, p=0.001), alanine aminotransferase (ALT) (26.55 U/L ± 23.82 vs. 19.57 U/L ± 20.81, p=0.002), aspartate aminotransferase (AST) (22.68 U/L ± 20.35 vs. 18.07 U/L ± 9.89, p=0.005), and glycosylated hemoglobin (HbA1c) (6.45% ± 1.69 vs. 5.76% ± 1.23, p=0.001) levels were higher in the MASLD group. In the MASLD group, HbA1c, AST, and ALT were significantly higher in the Grade 2-3 group than in the Grade 1 (p=0.038, p=0.038, p=0.001, respectively).
Conclusion
Elevated SUA levels are strongly linked to MASLD, particularly in males. Ease of measurement and low cost suggest that SUA could serve as a non-invasive biomarker for MASLD detection in at-risk groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Family Medicine, University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
- Department of Histology and Embryology, Faculty of Medicine, Baskent University, Ankara, Turkey.
- Department of Gastroenterology, University of Health Sciences, Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
- Department of Family Medicine, University of Health Sciences, Ankara Etlik City Hospital, Ankara, Turkey.
Zitieren
APA
Keskin, Ö., Özdemir, A., Üstün, Y., & Aypak, C. (2025). Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?. Gastroenterology and hepatology from bed to bench., 18(3), 342-352. https://doi.org/10.22037/ghfbb.v18i3.3033
Vancouver
Keskin Ö, Özdemir A, Üstün Y, Aypak C. Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?. Gastroenterology and hepatology from bed to bench.. 2025;18(3):342-352. doi:10.22037/ghfbb.v18i3.3033
BibTeX
@article{Keskin2025,
author = {Keskin, Ömer and Özdemir, Ayşe and Üstün, Yusuf and Aypak, Cenk},
title = {Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?},
journal = {Gastroenterology and hepatology from bed to bench.},
year = {2025},
volume = {18},
number = {3},
pages = {342--352},
doi = {10.22037/ghfbb.v18i3.3033}
}
EUVIMED